



# Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry

Provided by CDC's Elimination of Perinatal HIV Transmission Stakeholders Group

**WHEN:** Thursday, August 16, 2018 (60 minutes)

**TIME:** 12:00 pm ET

10:00 am MT

11:00 am CT

9:00 am PT


## PRESENTER:

- **William Short, MD, MPH, AAHIVS**  
University of Pennsylvania, Philadelphia, Pennsylvania



## WITH DISCUSSION AND COMMENTARY BY:

- **Lynne Mofenson, MD,**  
Elizabeth Glaser Pediatric AIDS Foundation
- **Jessica Albano, PhD, MPH**  
Executive Director, Epidemiology & Health Outcomes  
Real World & Late Phase, Syneos Health
- **Angela Scheuerle, MD**  
Professor, Department of Pediatrics, Division of Genetics and  
Metabolism; Professor, Department of Pathology, Division of Genetic  
Diagnostics; Professor, Eugene McDermott Center for Human Growth  
and Development, University of Texas, Southwestern Medical Center



## OBJECTIVES:

At the end of this webinar, participants will:

- Describe three objectives of the Antiretroviral Pregnancy Registry (APR).
- List two key findings from analysis of APR data.
- Describe four steps to report a drug exposure to the APR.

**TO REGISTER:** <http://aetc.adobeconnect.com/ehmqptol9x7p/event/registration.html>

Please feel free to share this invitation. For questions, please contact Macsu Hill at [hillma@sn.rutgers.edu](mailto:hillma@sn.rutgers.edu).  
Continuing education credit for this webinar is available. See page 2 for details.

# Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry

Provided by CDC's Elimination of Perinatal HIV Transmission Stakeholders Group

## ACCREDITATION STATEMENTS:

### CME activities with Joint Providers:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Centers for Disease Control and Prevention and the **FXB Center, Rutgers University School of Nursing** and the Antiretroviral Pregnancy Registry Advisory Committee. The Centers for Disease Control and Prevention is accredited by the (ACCME®) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Centers for Disease Control and Prevention designates this **enduring material** for a maximum of **1.0 AMA PRA Category 1 Credits™**.

**CNE:** The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.0** contact hours.

**CEU:** The Centers for Disease Control and Prevention is authorized by IACET to offer **0.1** CEU's for this program.

## DISCLOSURE:

In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the following exceptions. Dr. Albano wishes to disclose that she is a salaried employee of Syneos Health, the contract research organization responsible for the daily operations of the ARV Pregnancy Registry, including the statistical analysis. Dr. Albano also owns Syneos Health stock. Dr. Scheuerle wishes to disclose that she is a paid consultant to the ARV Pregnancy Registry. Dr. Short wishes to disclose paid consultancy and speaker fees for Janssen Therapeutics and paid consultancy for Gilead Sciences.

Planning committee discussed conflict of interest with Dr. Albano, Dr. Scheuerle, and Dr. Short to ensure there is no bias.

Presenters will be discussing potential off labeled use of drugs covered by APR.

The Antiretroviral Pregnancy Registry (APR) monitors antiretroviral (ARV) exposures during pregnancy. By registry definition, this includes monitoring of the off-label use of FDA-approved ARVs during pregnancy. *The APR does not make specific recommendations related to the use of specific ARVs during pregnancy.*

The Centers for Disease Control and Prevention, the FXB Center, Rutgers University School of Nursing, and the Antiretroviral Pregnancy Registry Advisory Committee are jointly providing the CNE for this activity.:

CDC did not accept commercial support for this activity.

## To receive continuing education (CE):

In order to receive CE for **Is It Safe? Safety Surveillance through the Antiretroviral Pregnancy Registry** please visit [TCEO](#) and follow these [9 Simple Steps](#) before 9/15/2018.

The course access code is APR2018

- Complete the activity
- Complete the Evaluation at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)
- Pass the posttest at 75% at [www.cdc.gov/GetCE](http://www.cdc.gov/GetCE)

**FEES:** There are no fees for CE